A positive association was found between osteoarthritis and overactive bladder (OAB), but rheumatoid arthritis and psoriatic ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...

Get an expert’s answers to common questions about how physical therapy can help with psoriatic arthritis, and learn how to get started. Living with psoriatic arthritis can mean chronic joint ...

More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

Women with psoriasis had increased risks for preeclampsia/eclampsia and cardiac arrhythmias during delivery hospitalizations, according to a real-world study evaluating maternal cardiovascular ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or ...

Understand RA from early to advanced stages. Explore symptoms, treatments, and lifestyle tips to manage rheumatoid arthritis ...

Rheumatoid arthritis (RA) is an autoimmune disease, an inflammatory arthritis, that often can present with much joint pain ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

In October 2024, Novartis announced that based on its review of 48-week data from the Phase 3 MANIFEST-2 study, longer follow-up time is needed to determine the regulatory path for pelabresib in ...